EN Bal oldali szöveges modul #3
For information
about our joint product
visit our sister site:

Details >>

pollenmap-hu
pollenterkep-mo
pollenmap-eu
pollenterkep-mo
Rhinolight
Read more
Investor info
Read more
Newsletter
Read more

News, events

2011. October 05.
Rhinolight at MEDICA Düsseldorf 2011
On November 16-19, 2011, the Rhinolight® phototherapeutic device will be exhibited for the the seventh consecutive time in the history of the MEDICA Trade Fair held in Düsseldorf. Rhinolight Ltd. will participate the event as an exhibitor this time as well. >>
2010. November 30.
The new web site of the Skinolight® phototherapy is now available
Web site of the Skinolight® phototherapy is now available in English and Hungarian. >>
2010. October 14.
Rhinolight at MEDICA Düsseldorf 2010
On November 17-20, 2010, the Rhinolight® phototherapeutic device was exhibited for the the sixth consecutive time in the history of the MEDICA Trade Fair held in Düsseldorf. Rhinolight Ltd.  participated the event as an exhibitor this time as well. The fair porved to be successful for the company as many of Medica's record number of visitors showed up at Rhinolight's stand. >>

Video

more videos >>

Introduction

Rhinolight® Ltd. is a Szeged-based spin-off Hungarian SME, established in 2003 to utilize the patent of the Rhinolight® phototherapeutic device. Rhinolight® is the only clinically justified phototherapy for the treatment of allergic rhinitis. Its efficacy and safety have been proven by a number of articles published in international scientific journals. There are some 60 Rhinolight® treatment centers in Hungary, while since 2004 the company has had an active export activity in 19 countries with the help of distribution partners and individual users.
In addition to already available indications, our most recent development is the dermatological application of Rhinolight®, which is marketed as Skinolight® in commercial use. The latest and really promising application of the Rhinolight® phototherapy is the treatment of nasal polyps. The special tool developed for this purpose is currently being tested within the framework of our Hungarian clinical trial with the highest number of patients so far.